Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 124

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 124
---
 protection for improvements in the products and the processes of manufacture.

Specifically, while the basic
patent estate (patent family derived from WO 2005/061018) has expiration dates in December 2025, additional patent families of the Company,
have later expiration dates, and cover improvements as detailed herein. In particular, while the basic patent estate is directed to the
specific ingredients of Gelrin, the latest family of patents and patent applications (derived from WO 2017/103924) is instead directed
to a final product (GelrinC). The latest patent applications derived from WO 2017/103924 have already been granted in China, India and
Israel. Other patent applications in the WO 2017/103924 are in an examination process, which will determine if they also mature into
actual patents. The product covered by WO 2017/103924 uses a ready–for–use formulation technology which is employed in the
final product. WO 2017/103924 also covers a process of manufacturing of GelrinC that avoids the use of acetone, which may become forbidden
under advanced guidelines for products introduced into the body. Therefore, we believe that upon approval in different territories, additional
patents could provide the Company with sufficient protection from completion even after the expiration dates of the basic patent estate.

GelrinC

The Gelrin technology utilizes
a conjugate of denatured fibrinogen and polyethylene glycol and the intended clinical use of this product is to treat focal cartilage
injuries. These specific conjugate molecules are disclosed and claimed in the earliest patent family of the Company derived from WO 2005/061018,
which are nominally due to expire in December 2025. In various countries, patent term extension or supplementary protection certificates
are available upon receipt of marketing approval to prolong the period of exclusivity of a new medical product. The earliest patent family
of the Company derived from WO 2005/061018 includes patents Nos. US 8,007,774, US 8,858,925, US 9,120,872 and EP 1870115, which are detailed
in the table below.

While the first family of
patents form the “basic patent estate” covering the current products of the Company, diligent efforts have been made by the
Company to cover improvements and alternatives. Our “basic patent estate” has expiration date in December 2025.